(article reprinted from IACP’s Capitol Connectionsnewsletter, Sept 11, 2013)
By IACP Member Linda F. McElhiney, PharmD, RPh, FIACP, FASHP, FACA
After attending IACP’s 2013 Compounders on Capitol Hill, I spoke to our VP of Government Affairs at Indiana University Health about the proposed S.959 bill, and sent her the information that was provided to the Congressman. Within a few weeks, we had conference calls with the American Hospital Association (AHA), the Children’s Hospital Association (CHA), and members of theSenate HELP Committee to discuss how S.959 was going to have a negative impact upon hospital compounding practices, such as anticipatory or batch compounding, compounding for hospital subsidiaries, compounds as “new drugs,” notification to the FDA for compounded backorder items, and the FDA “Do Not Compound” list. The discussions were very positive and I think that we are gaining support for changes to the S.959 from the various hospital organizations.
continue to read here
No comments:
Post a Comment